Clinical trials: High Grade Glioma
Glioblastoma, Gliosarcoma
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
This is a Phase I study of Nanoliposomal CPT-11 in patients with Recurrent high-grade gliomas. Patients must have a histologically proven intracranial malignant glioma, which includes glioblastoma multiforme (GBM), gliosarcoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734682
- Testing
- Nanoliposomal CPT-11
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
Fenretinide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent…
- Trial name
- NCT00006080
- Testing
- fenretinide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Malignant Glioma
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive).
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
- Trial name
- NCT04323046
- Testing
- Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 20 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Sabine Mueller, MD, PhD
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Malignant Glioma, Glioblastoma Multiforme
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00041587
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma, High-Grade Glioma (WHO III-IV)
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), Glioblastoma (GBM)
- Trial name
- NCT07488754
- Testing
- Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
Brain and Central Nervous System Tumors
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00014573
- Testing
- aldesleukin, autologous tumor cell vaccine, filgrastim
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Glioblastoma Multiforme, Gliosarcoma
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ).
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734864
- Testing
- enzyme-inducing anti-epileptic drugs
- Where
- United States
- Sponsor
- Annick Desjardins
Glioblastoma, Gliosarcoma
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Primary objective To determine maximum tolerated dose \& dose limiting toxicity of imatinib mesylate \& RAD001 when combined w fixed doses of hydroxyurea among pts w recurrent GBM who are on \& not on enzyme-inducing…
- Trial name
- NCT00613132
- Testing
- Gleevec, RAD001, and Hydroxyurea
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Annick Desjardins
Malignant Glioma of Brain, Astrocytoma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor
- Trial name
- NCT05686798
- Testing
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Glioblastoma, Glioblastoma Multiforme
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
- Trial name
- PALSUR (NCT06146738)
- Testing
- Palliative Care, Tumor biopsy, Tumor resection
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 1,015 people
- Sponsor
- Jasper Gerritsen
Malignant Glioma, Glioblastoma Multiforme
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine IL13 and a toxin from the bacterium…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00064779
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Malignant Glioma
Early Palliative Care Intervention in Malignant Glioma
The purpose of this research study is to determine the feasibility and acceptability of incorporating palliative care into the clinical care plans of patients newly diagnosed with malignant brain tumors.
- Trial name
- NCT03471546
- Testing
- Palliative Care
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Grade IV Astrocytoma, Glioblastoma
Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
O6-méthylguanine méthyltransférase (MGMT) is the main repair gene after DNA lesion induced by Temozolomide in combination with radiation therapy of Glioblastoma (GBM) in Stupp.R et al published regimen.
- Trial name
- FOLAGLI (NCT01700569)
- Testing
- Temozolomide, folinic acid at pharmacological dose is the escalated drug, High voltage radiation therapy (linear accelerator)
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Cancerologie de l'Ouest
Malignant Gliomas
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide combined with Camptosar (irinotecan) as well as to see if this drug combination can help control malignant gliomas.
- Trial name
- NCT00671801
- Testing
- Irinotecan, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Glioma, Medulloblastoma
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.
- Trial name
- NCT00404495
- Testing
- Irinotecan, Temozolomide
- Where
- 29 sites in Australia, Belgium and 6 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Glioma
MR Perfusion Methods in Patients With Suspected Recurrent High Grade Gliomas
Radiation therapy is an important adjunct in the treatment of patients with glioma, although a common side effect is radiation-induced injury of brain parenchyma.
- Trial name
- NCT02919865
- Testing
- MR perfusion imaging
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
RATIONALE: Acupressure wristbands may prevent or reduce nausea and caused by chemotherapy. It is not yet known whether standard care is more effective with or without acupressure wristbands in controlling acute and delayed…
- Conditions
- Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- SCUSF1202 (NCT01346267)
- Testing
- Real Acupressure Band
- Where
- 25 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- University of South Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.